Native GLP-1 (7-36 Amide): Why "Pure GLP-1" Fails as a Drug

At a Glance

GLP-1 is the hormone the entire weight-loss drug market is built on. Semaglutide, liraglutide, tirzepatide and retatrutide are all engineered to imitate it. So the appeal of a vial labelled “pure GLP-1” or “GLP-1 7-36 amide” is obvious: why take the copy when you can have the original?

The honest verdict comes first, because it is unusually clear-cut. Native GLP-1 is the real hormone, it demonstrably works when infused continuously, and it is close to worthless as a subcutaneous injection. Human plasma inactivates it within about two minutes. The fifteen-year engineering effort that produced today’s incretin medicines existed to solve exactly that problem.

This page is therefore less a buyer’s guide than the piece of pharmacology that explains the rest of the category. Understand why native GLP-1 failed and you understand why liraglutide is daily, why semaglutide is weekly, and why the numbers on those labels look nothing like physiological hormone levels.

How it works

GLP-1 is cut from proglucagon in intestinal L-cells and released within minutes of eating. The active forms are GLP-1 (7-36) amide — the dominant circulating version in humans — and GLP-1 (7-37). At the GLP-1 receptor, a class B G-protein-coupled receptor, it does several things at once:

• Glucose-dependent insulin secretion. It amplifies insulin release from beta cells only when glucose is elevated. That dependence is why it does not cause hypoglycaemia on its own: at normal glucose, the amplification switches off.
• Glucagon suppression, which reduces hepatic glucose output — the effect that normalised fasting glucose in Nauck’s 1993 infusion study.
• Slowed gastric emptying, which flattens post-meal glucose excursions and contributes to fullness.
• Central satiety signalling through vagal afferents and hypothalamic GLP-1 receptors.

Kreymann and colleagues established it as a physiological incretin in humans in 1987, one of the cleanest first-in-human hormone characterisations in endocrinology [1]. Holst’s 2007 Physiological Reviews synthesis and Drucker’s 2018 mechanistic review remain the standard references for the receptor biology [9, 10].

Then comes the catch. Dipeptidyl peptidase-4 (DPP-4), an enzyme abundant on endothelium and in plasma, cleaves the N-terminal His-Ala dipeptide. Deacon’s 1995 work showed directly that human plasma converts GLP-1 (7-36) amide into GLP-1 (9-36) amide, and that this truncated metabolite is the major circulating form in vivo [3]. GLP-1 9-36 does not meaningfully activate the receptor; renal clearance removes the rest. Net result: a plasma half-life on the order of one to two minutes.

Every approved GLP-1 medicine is an answer to that single enzyme. Knudsen’s 2000 paper describing the acylated derivatives that became liraglutide states the design problem plainly: substitute the DPP-4 cleavage site, attach a fatty acid for albumin binding, and the half-life goes from minutes to hours or days [11].

What the evidence shows

Human infusion studies: the hormone works

Insulin secretion and glucose normalisation. In ten people with poorly controlled type 2 diabetes (HbA1c 11.6%), intravenous GLP-1 (7-36) amide at 1.2 pmol/kg/min in the fasting state raised insulin and C-peptide, suppressed glucagon, and brought plasma glucose from 13.1 mmol/L down to normal fasting values [2]. That is a striking result for a hormone infusion in advanced diabetes.

Appetite and food intake. In 20 healthy normal-weight men studied in a placebo-controlled crossover design, GLP-1 infusion at 50 pmol/kg/h increased satiety and fullness ratings and cut spontaneous energy intake at an ad libitum lunch by 12% [4]. Gutzwiller’s 1999 Gut study found the same direction of effect in lean and obese participants [5]. Verdich’s 2001 meta-analysis pooled individual subject data (n = 115) across infusion studies and found a dose-dependent reduction in ad libitum energy intake, with earlier negative studies explained by low infusion rates and insufficient power [6].

Six weeks of continuous infusion. The most clinically informative study is Zander’s 2002 Lancet parallel-group trial of continuous subcutaneous GLP-1 infusion for six weeks in type 2 diabetes. Fasting and 8-hour mean glucose fell by 4.3 and 5.5 mmol/L, HbA1c fell by 1.3%, free fatty acids dropped by 23–30%, gastric emptying was inhibited, appetite was reduced, body weight fell by 1.9 kg, and both insulin sensitivity and beta-cell function improved, with no important side effects reported [7]. This is the proof that sustained GLP-1 receptor exposure is therapeutic — and it took a pump running continuously for six weeks to produce it.

Cardiac data. Nikolaidis’s 2004 Circulation study infused GLP-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion, reporting improved ejection fraction and regional wall motion [8]. Mechanistically interesting, small, and never developed into an outcome programme because the delivery problem was unsolved.

What no study shows

There is no trial of subcutaneous bolus native GLP-1 for weight loss, glycaemic control, or anything else. There is not even a published pharmacokinetic study of a 1 mg subcutaneous bolus in humans. The molecules that went on to outcome trials are the ones built to survive DPP-4.

That asymmetry is the whole story: strong physiology, zero evidence for the delivery method actually being sold.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Converting the trial numbers is instructive. At 1.2 pmol/kg/min an 80 kg adult receives roughly 96 pmol/min — about 0.32 mcg/min, or 460 mcg over 24 hours, delivered continuously. A single 250 mcg subcutaneous bolus therefore contains a plausible 24-hour dose of hormone, which is then cleared with a half-life of roughly two minutes: receptor occupancy high for a few minutes, effectively gone within half an hour. Transient nausea and fullness are predictable. The 24-hour exposure that produced the trial results is not achievable this way.

Titration. There is nothing to titrate. Protocols that mimic semaglutide-style weekly escalation are applying the logic of a long-acting analogue to a two-minute hormone.

Stacks commonly described. Forum and vendor protocols pair native GLP-1 with a DPP-4 inhibitor (sitagliptin, linagliptin) on the theory that blocking the degrading enzyme extends its life. The direction is right and the magnitude is inadequate: DPP-4 inhibition roughly doubles endogenous active GLP-1 levels, which is why gliptins are modest glucose-lowering agents rather than weight-loss drugs. It does not turn a two-minute peptide into a daily one, and it adds a prescription drug and its interactions to an unapproved injection. I would not do it.

For reconstitution, needle choice and injection technique, see the existing peptide injection guide. For how the approved members of this class are actually dosed, the liraglutide and tirzepatide pages give the label schedules.

What people report: what works and what doesn’t

Sources here are the published infusion literature, the 2026 peer-reviewed review of self-administered peptide use [12], the open community record on forums such as r/Peptides, and protocol compilations such as peptidedosingprotocols.com. Community material is pattern, not proof, and no individual account is treated as evidence.

Reported to work

• Acute, short-lived appetite and fullness effects in the 30–60 minutes after injection, often described as “it worked for one meal”. Consistent with the infusion satiety data [4, 5] and with a two-minute half-life.
• Slowed digestion and early satiety on the same timescale.

Mixed or unclear

• Multi-week weight loss attributed to native GLP-1. Such reports exist, but typically alongside calorie restriction started at the same time, and they are the exception rather than the pattern — the opposite of the near-uniform reports on semaglutide and tirzepatide.
• Claimed benefit when stacked with a DPP-4 inhibitor: plausible in direction, unquantified, and confounded by the second drug.

Reported not to work / disappointing

• Sustained appetite suppression between doses. This is the most consistent disappointment, and it is the predicted one.
• Anything resembling the weight-loss trajectory of approved analogues. People who switch from native GLP-1 to semaglutide or tirzepatide describe the difference as categorical.
• Oral or nasal preparations of the native hormone: no reported effect, as expected from peptide digestion.
• Side effects described are the familiar incretin profile in miniature — nausea, bloating, early fullness — concentrated in the hour after injection.

What a properly designed human trial would need to show: that a defined subcutaneous bolus of GLP-1 (7-36) amide produces receptor-relevant plasma concentrations for a clinically meaningful fraction of the dosing interval, and that this translates into weight or HbA1c change against placebo. No such pharmacokinetic study exists, and the enzymology makes a positive result unlikely.

Safety and side effects

The infusion studies were well tolerated. Zander reported no important side effects over six weeks of continuous infusion [7]; acute infusions produce nausea at higher rates, as expected from the class. Because the insulinotropic effect is glucose-dependent, hypoglycaemia risk from the hormone alone is low — but it is not low in combination with insulin or sulfonylureas, where the usual dose-reduction logic applies.

Concerns specific to self-administered native GLP-1:

• Quality and identity. “Research use only” material is not manufactured or tested for human administration. GLP-1 7-36 amide is prone to degradation and aggregation with improper storage, and the buyer cannot confirm content, purity, sterility or endotoxin level. See peptide sourcing for the checks that do exist.
• Unknowns. There is no human safety data set for repeated subcutaneous bolus administration, because nobody has studied it.
• Contraindications borrowed from the class. Personal or family history of medullary thyroid carcinoma or MEN2, prior pancreatitis, pregnancy and breastfeeding, and severe gastroparesis are all reasons the approved analogues are withheld. The same cautions apply here, without any of the label-level data behind them.
• Interactions. Delayed gastric emptying can alter absorption of oral drugs with narrow therapeutic windows.

Legal and regulatory status

United States. Not an approved drug. Native GLP-1 does not appear in 503A category 1, so the FDA’s interim enforcement policy for compounding does not cover it; what the categories actually mean is covered in the FDA 2026 compounding update. Vials are sold under “research use only” labelling, which is a distribution route, not a safety claim.

European Union and Germany. No EMA marketing authorisation. Importing research chemicals for personal injection is legally exposed, and administering an unapproved substance to another person falls outside the medicinal-products framework entirely. Approved GLP-1 receptor agonists are available on prescription.

Sport. Non-approved substances fall under WADA category S0 and are prohibited at all times, in and out of competition — see peptides and WADA rules.

How it fits: native hormone vs engineered analogues

The table is the argument. Native GLP-1 is the molecule the rest of the class was built from, and its position at the bottom of every practical column is not an accident of research funding — it is the direct consequence of DPP-4 cleavage. If someone offers you “the original, unmodified version”, what they are offering is the version that could not be made into a medicine.

Where native GLP-1 remains genuinely interesting is as a research tool for probing incretin physiology, and as the reference point for judging new analogues: every claim about a novel GLP-1 agonist should be read against what the hormone itself does when it is delivered properly.

Related Articles

• Semaglutide: Beyond Weight Loss — A Physician’s Assessment — the analogue that defined the category.
• Liraglutide: The First GLP-1 for Weight Loss, Reassessed — the first solution to the half-life problem.
• Tirzepatide: The Dual GIP/GLP-1 Agonist in Full — where the class stands now.
• Retatrutide vs Semaglutide vs Tirzepatide — single, dual and triple agonism compared.
• VK2735 Oral GLP-1 Peptide — the oral delivery problem and current attempts to solve it.
• Peptide Sourcing: Pharmaceutical-Grade vs Grey Market — what “research use only” actually means.